Logo image of BDSX

BIODESIX INC (BDSX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BDSX - US09075X2071 - Common Stock

6.83 USD
+0.32 (+4.92%)
Last: 11/21/2025, 8:13:29 PM
8 USD
+1.17 (+17.13%)
After Hours: 11/14/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BDSX. BDSX was compared to 100 industry peers in the Health Care Providers & Services industry. BDSX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, BDSX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BDSX had negative earnings in the past year.
BDSX had a negative operating cash flow in the past year.
In the past 5 years BDSX always reported negative net income.
In the past 5 years BDSX always reported negative operating cash flow.
BDSX Yearly Net Income VS EBIT VS OCF VS FCFBDSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -45.74%, BDSX is not doing good in the industry: 90.00% of the companies in the same industry are doing better.
BDSX's Return On Equity of -3530.70% is on the low side compared to the rest of the industry. BDSX is outperformed by 84.00% of its industry peers.
Industry RankSector Rank
ROA -45.74%
ROE -3530.7%
ROIC N/A
ROA(3y)-55.77%
ROA(5y)-49.98%
ROE(3y)-552.62%
ROE(5y)-390.61%
ROIC(3y)N/A
ROIC(5y)N/A
BDSX Yearly ROA, ROE, ROICBDSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

BDSX's Gross Margin of 78.77% is amongst the best of the industry. BDSX outperforms 93.00% of its industry peers.
BDSX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BDSX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
BDSX Yearly Profit, Operating, Gross MarginsBDSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

BDSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BDSX has more shares outstanding than it did 1 year ago.
BDSX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BDSX has a worse debt to assets ratio.
BDSX Yearly Shares OutstandingBDSX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
BDSX Yearly Total Debt VS Total AssetsBDSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.56, we must say that BDSX is in the distress zone and has some risk of bankruptcy.
BDSX's Altman-Z score of -7.56 is on the low side compared to the rest of the industry. BDSX is outperformed by 91.00% of its industry peers.
A Debt/Equity ratio of 41.23 is on the high side and indicates that BDSX has dependencies on debt financing.
BDSX has a worse Debt to Equity ratio (41.23) than 85.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 41.23
Debt/FCF N/A
Altman-Z -7.56
ROIC/WACCN/A
WACC13.32%
BDSX Yearly LT Debt VS Equity VS FCFBDSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 2.13 indicates that BDSX has no problem at all paying its short term obligations.
BDSX's Current ratio of 2.13 is fine compared to the rest of the industry. BDSX outperforms 79.00% of its industry peers.
A Quick Ratio of 2.13 indicates that BDSX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 2.13, BDSX is doing good in the industry, outperforming 80.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.13
Quick Ratio 2.13
BDSX Yearly Current Assets VS Current LiabilitesBDSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for BDSX have decreased strongly by -1033.33% in the last year.
Looking at the last year, BDSX shows a very strong growth in Revenue. The Revenue has grown by 45.30%.
The Revenue has been growing by 23.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1033.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1557.14%
Revenue 1Y (TTM)45.3%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%19.93%

3.2 Future

BDSX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -77.53% yearly.
BDSX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.80% yearly.
EPS Next Y-1473.71%
EPS Next 2Y-218.46%
EPS Next 3Y-77.53%
EPS Next 5YN/A
Revenue Next Year17.68%
Revenue Next 2Y21.96%
Revenue Next 3Y21.8%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BDSX Yearly Revenue VS EstimatesBDSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
BDSX Yearly EPS VS EstimatesBDSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BDSX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BDSX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDSX Price Earnings VS Forward Price EarningsBDSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDSX Per share dataBDSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as BDSX's earnings are expected to decrease with -77.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-218.46%
EPS Next 3Y-77.53%

More info and screens

0

5. Dividend

5.1 Amount

BDSX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIODESIX INC

NASDAQ:BDSX (11/21/2025, 8:13:29 PM)

After market: 8 +1.17 (+17.13%)

6.83

+0.32 (+4.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)03-02 2026-03-02/bmo
Inst Owners22.98%
Inst Owner Change-95.68%
Ins Owners25.97%
Ins Owner Change1.72%
Market Cap50.06M
Revenue(TTM)71.32M
Net Income(TTM)-40.25M
Analysts80
Price Target33.15 (385.36%)
Short Float %6.16%
Short Ratio0.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.06%
Min EPS beat(2)-15.34%
Max EPS beat(2)-14.78%
EPS beat(4)2
Avg EPS beat(4)-2.99%
Min EPS beat(4)-15.34%
Max EPS beat(4)11.77%
EPS beat(8)6
Avg EPS beat(8)3.3%
EPS beat(12)8
Avg EPS beat(12)1.74%
EPS beat(16)11
Avg EPS beat(16)2.05%
Revenue beat(2)1
Avg Revenue beat(2)-1.63%
Min Revenue beat(2)-9.55%
Max Revenue beat(2)6.29%
Revenue beat(4)2
Avg Revenue beat(4)-1.73%
Min Revenue beat(4)-9.55%
Max Revenue beat(4)6.29%
Revenue beat(8)4
Avg Revenue beat(8)-1.48%
Revenue beat(12)6
Avg Revenue beat(12)-1.3%
Revenue beat(16)8
Avg Revenue beat(16)0.19%
PT rev (1m)0%
PT rev (3m)1844.44%
EPS NQ rev (1m)7.1%
EPS NQ rev (3m)-1900%
EPS NY rev (1m)4.42%
EPS NY rev (3m)-2119.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.03%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)1.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.65
P/FCF N/A
P/OCF N/A
P/B 50.06
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.42
EYN/A
EPS(NY)-3.55
Fwd EYN/A
FCF(TTM)-4.28
FCFYN/A
OCF(TTM)-4.09
OCFYN/A
SpS10.44
BVpS0.14
TBVpS-2.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.74%
ROE -3530.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.77%
FCFM N/A
ROA(3y)-55.77%
ROA(5y)-49.98%
ROE(3y)-552.62%
ROE(5y)-390.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
F-Score3
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 41.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.06%
Cap/Sales 1.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.13
Quick Ratio 2.13
Altman-Z -7.56
F-Score3
WACC13.32%
ROIC/WACCN/A
Cap/Depr(3y)282.79%
Cap/Depr(5y)200.75%
Cap/Sales(3y)20.31%
Cap/Sales(5y)14.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1033.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1557.14%
EPS Next Y-1473.71%
EPS Next 2Y-218.46%
EPS Next 3Y-77.53%
EPS Next 5YN/A
Revenue 1Y (TTM)45.3%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%19.93%
Revenue Next Year17.68%
Revenue Next 2Y21.96%
Revenue Next 3Y21.8%
Revenue Next 5YN/A
EBIT growth 1Y-2.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.14%
EBIT Next 3Y31.94%
EBIT Next 5YN/A
FCF growth 1Y31.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.34%
OCF growth 3YN/A
OCF growth 5YN/A

BIODESIX INC / BDSX FAQ

Can you provide the ChartMill fundamental rating for BIODESIX INC?

ChartMill assigns a fundamental rating of 2 / 10 to BDSX.


Can you provide the valuation status for BIODESIX INC?

ChartMill assigns a valuation rating of 0 / 10 to BIODESIX INC (BDSX). This can be considered as Overvalued.


Can you provide the profitability details for BIODESIX INC?

BIODESIX INC (BDSX) has a profitability rating of 1 / 10.


Can you provide the financial health for BDSX stock?

The financial health rating of BIODESIX INC (BDSX) is 3 / 10.


What is the expected EPS growth for BIODESIX INC (BDSX) stock?

The Earnings per Share (EPS) of BIODESIX INC (BDSX) is expected to decline by -1473.71% in the next year.